Modulation of tubulin tyrosinolation in human polymorphonuclear leukocytes (PMM).
D000693:Anaerobiosis; D000975:Antioxidants / Q000494:pharmacology; D001205:Ascorbic Acid / Q000494:pharmacology; D002268:Carboxypeptidases / Q000378:metabolism; D002609:Chediak-Higashi Syndrome / Q000378:metabolism; D003512:Cyclohexanones / Q000494:pharmacology; D003958:Diamide / Q000494:pharmacology; D006105:Granulomatous Disease, Chronic / Q000378:metabolism; D006801:Humans; D008751:Methylene Blue / Q000494:pharmacology; D009240:N-Formylmethionine Leucyl-Phenylalanine / Q000494:pharmacology; D009504:Neutrophils / Q000378:metabolism* / Q000502:physiology / Q000648:ultrastructure; D010084:Oxidation-Reduction; D010453:Peptide Synthases / Q000378:metabolism; D011499:Protein Processing, Post-Translational / Q000187:drug effects; D014404:Tubulin / Q000378:metabolism*; D014443:Tyrosine / Q000378:metabolism
D000975:Antioxidants; D003512:Cyclohexanones; D014404:Tubulin; D003958:Diamide; D014443:Tyrosine; C028215:2-cyclohexen-1-one; D009240:N-Formylmethionine Leucyl-Phenylalanine; D002268:Carboxypeptidases; C023212:tyrosyltubulin carboxypeptidase; D010453:Peptide Synthases; C023213:tyrosyltubulin ligase; D001205:Ascorbic Acid; D008751:Methylene Blue